Related references
Note: Only part of the references are listed.Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
Estefania Garcia-Guerrero et al.
LEUKEMIA (2021)
Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients
Chantal Reina-Ortiz et al.
ONCOIMMUNOLOGY (2021)
Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment
Benjamin Motais et al.
CELLS (2021)
Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs
Cristina Capuano et al.
CANCERS (2021)
The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide
Subhashis Sarkar et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
Nizar J. Bahlis et al.
LEUKEMIA (2020)
CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity
Meisam Naeimi Kararoudi et al.
BLOOD (2020)
TAK-573, an anti-CD38-targeted attenuated interferon alpha (IFNα) fusion protein, showed anti-myeloma tumor responses in combination with standard of care (SOC) agents in multiple myeloma (MM) xenograft tumor models in vivo
Marjan Fatholahi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
Homer C. Adams et al.
CYTOMETRY PART A (2019)
Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions
Niken M. Mahaweni et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo-Expanded Autologous NK Cells
Yufeng Wang et al.
CLINICAL CANCER RESEARCH (2018)
Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update
Hanley N. Abramson
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
Brent A. Williams et al.
ONCOTARGET (2017)
Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
Shih-Feng Cho et al.
ANTIBODIES (2017)
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
Tineke Casneuf et al.
BLOOD ADVANCES (2017)
Rationally engineered Cas9 nucleases with improved specificity
Ian M. Slaymaker et al.
SCIENCE (2016)
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
Inger S. Nijhof et al.
BLOOD (2016)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
All-trans retinoic acid and interferon-α increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors
K. Mihara et al.
BLOOD CANCER JOURNAL (2016)
Immuno-targeting the multifunctional CD38 using nanobody
Ting Li et al.
SCIENTIFIC REPORTS (2016)
CD38 Monoclonal Antibody Therapies for Multiple Myeloma
Sandy W. Wong et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
I. S. Nijhof et al.
LEUKEMIA (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Daratumumab granted breakthrough drug status
Jacob P. Laubach et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Torsten Tonn et al.
CYTOTHERAPY (2013)
The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential
Beatrice Clemenceau et al.
MABS (2013)
Impact of the NK Cell Receptor LIR-1 (ILT-2/CD85j/LILRB1) on Cytotoxicity against Multiple Myeloma
Silke Heidenreich et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
S. Arai et al.
CYTOTHERAPY (2008)
Phosphatidylinositol 3-kinases are involved in the all-trans retinoic acid-induced upregulation of CD38 antigen on human haematopoietic cells
D Lewandowski et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Human CD38: a (r)evolutionary story of enzymes and receptors
S Deaglio et al.
LEUKEMIA RESEARCH (2001)
Share Paper
